Showing results (221-230 of 427) with videos related to

Sort By:
Pageof 43
Journal of Clinical Medicine|August 26, 2023
Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA SurveyMassimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, et al.
Leukemia Research|August 19, 2007
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rateGiuliana Alimena, Massimo Breccia, Luigia Luciano, et al.
Leukemia & Lymphoma|May 23, 2015
Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular responseRoberto Latagliata, Angela Romano, Marco Mancini, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 29, 2014
Early and late complications related to central venous catheters in hematological malignancies: a retrospective analysis of 1102 patientsSalvatore Giacomo Morano, Lorenzo Coppola, Roberto Latagliata, et al.
Haematologica|May 14, 2026
Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in ItalyMassimo Breccia, Alessandra Iurlo, Fabrizio Pane, et al.
International Journal of Hematology|August 25, 2009
Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term resultsRoberto Latagliata, Angela Rago, Antonio Spadea, et al.
Haematologica|November 22, 2011
Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experienceCorrado Girmenia, Anna Maria Frustaci, Giuseppe Gentile, et al.
Acta Haematologica|December 5, 2012
Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemiaRoberto Latagliata, Alessandro Isidori, Massimo Breccia, et al.
Blood|November 4, 2011
Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocolsMassimo Breccia, Luca Mazzarella, Vincenzo Bagnardi, et al.
BMJ Supportive & Palliative Care|July 19, 2020
Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burdenKathrin Sommer, Marco Vignetti, Francesco Cottone, et al.
Pageof 43